Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 8/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.52 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.52 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481742 | 1.00 | MDM2 (0.67) | MDM2LRRK2ERBB2EGFRNPC1 | |
| SCHEMBL5469894 | 0.89 | MDM2 (0.74) | MDM2LRRK2ERBB2EGFRNPC1 | |
| SCHEMBL5469888 | 0.89 | MDM2 (0.74) | MDM2LRRK2ERBB2EGFRNPC1 | |
| SCHEMBL5368659 | 0.86 | NPC1 (0.57) | MDM2LRRK2EGFRNPC1 | |
| SCHEMBL6001164 | 0.85 | TLK2 (0.60) | MDM2NPC1 | |
| SCHEMBL5477376 | 0.84 | NPC1 (0.80) | MDM2ERBB2NPC1PDGFRBFLT3 | |
| SCHEMBL5477373 | 0.84 | NPC1 (0.80) | MDM2ERBB2NPC1PDGFRBFLT3 | |
| SCHEMBL5480416 | 0.82 | LRRK2 (0.78) | MDM2LRRK2ERBB2EGFRPSEN1 | |
| SCHEMBL5480412 | 0.82 | LRRK2 (0.78) | MDM2LRRK2ERBB2EGFRPSEN1 | |
| SCHEMBL5376631 | 0.81 | SYK (0.58) | MDM2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | MDM2 4274/4885LRRK2 1753/4885ERBB2 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.